Prolastin United States
United States  |   For US Healthcare Professionals Only

 Advanced Search
Print This Page
Patients and Consumers
Prolastin® (alpha-1 proteinase inhibitor [human]) has a history of commitment, convenience, and care for people with alpha-1 antitrypsin (AAT) deficiency.

Prolastin®, first launched in 1988, was
the only alpha1-proteinase inhibitor available
to patients for over 15 years. As a result of this continuous commitment, you can expect the most in convenience and care when you treat with Prolastin®:

elevates AAT levels1
has been shown to improve survival rate and slow FEV1 decline2,3*
is well tolerated
is easy to dose

In addition, since it was first available, there have been over 2 million doses of Prolastin® provided to adults with alpha1-antitrypsin (AAT) deficiency, with no confirmed reports of viral transmission.

Learn more About Prolastin®

*Nonrandomized/uncontrolled trials.

References:

1.   Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316:1055-1062.
2.   Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1998;158:49-59.
3.   Schwaiblmair M, Vogelmeier C, Fruhmann G. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency—three-year follow-up. Respiration. 1997;64:10-15.


Important Safety Information

Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for Prolastin® full Prescribing Information.

Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.

When your patients need alpha1-antitrypsin augmentation therapy, be sure to enroll them in Prolastin Direct ™
Test for AAT deficiency using a validated, simple testing method.
Access educational materials for your patients, including a Starter Kit.
Prolastin® Home  |   About Prolastin®  |   Understanding Alpha1-Antitrypsin Deficiency  |   Alpha1-Antitrypsin Deficiency Diagnosis & Treatment
Prolastin® Clinical Data  |   Prolastin DirectSM  |   Tools & Resources  |   Prescribing Information  |   For Patients and Consumers  |   Site Map



 
  Talecris Biotherapeutics   Contact Talecris    General Conditions of Use    Privacy Statement    Contact Prolastin®
 
This site is intended for US residents only. Non-US residents can go to www.Talecris.com.
© 2007 Talecris Biotherapeutics, Inc.